Biovest International has announced a continuing collaboration with the Naval Health Research Center (NHRC) to study Biovest’s hollow fiber technology. The collaboration is being conducted as a shared resource within the NHRC’s Respiratory Disease Laboratory in San Diego, California. This research collaboration is evaluating the potential use of Biovest’s platform systems for the efficient cell culture production of difficult-to-produce biologics including live viral vaccines, virus-like particles and diagnostic reagents.
According to Biovest’s consulting medical advisor, Dr. J. David Gangemi, Ph.D., Professor Emeritus, Microbiology and Molecular Medicine, Clemson University, “Biovest’s hollow fiber systems have proven to be highly efficient, cost-effective bioreactors for the production of monoclonal antibodies, recombinant proteins and personalized cancer vaccines. We are now evaluating if Biovest’s novel hollow fiber technology also represents an ideal cell culture platform for the rapid propagation of virus for the efficient manufacture of many kinds of vaccines and other products of military importance. Encouragingly, our preliminary viral growth results suggest multiple key fundamental advantages not found in other bioreactor systems currently used for virus production.”
Biovest’s Chief Scientific Officer, Dr. Mark Hirschel, Ph.D., added, “We are collaborating with NHRC to conduct multiple viral growth studies using our hollow fiber bioreactor systems. The intent is to demonstrate the key benefits and advantages of this technology over more established conventional methods routinely used for the production of viral vaccines. It is our goal to position the AutovaxID™ and our other hollow fiber systems as a preferred flexible, robust manufacturing platform for the production of emerging pandemic viruses and vaccines.”
Biovest is a Tampa-based majority-owned subsidiary of Accentia Biopharmaceuticals, Inc.